Table 1.

Demographic clinical data of patients with SSc.

	SSc within 2 years after diagnosis (n = 12)	SSc over 2 years after diagnosis (n = 21)	p value
Age, years	50.1 ± 12.9	55.1 ± 12.6	0.27
Female, n (%)	6 (50)	16 (76)	0.12
Disease duration, median(IQR), years	0.40 (0.11-0.97)	4.7 (3.0-17.6)	<0.0001
Diffuse SSc, n (%)	10 (83)	13 (62)	0.22
Interstitial pneumonia, n (%)	8 (67)	16 (76)	0.69
Pulmonary arterial hypertension, n (%)	1 (8.3)	7 (33)	0.21
modified Rodnan skin score	20.3 ± 9.0	13.3 ± 11.2	0.21
Autoantibodies
Anti-Scl70 antibody positive, n (%)	6 (50)	6 (30)	0.26
Anti-centromere antibody positive, n (%)	1 (8.3)	5 (25)	0.38
Anti-RNA polymeraseIII antibody positive, n (%)	2 (17)	2 (10)	0.61
Anti-RNP antibody positive, n (%)	2 (17)	6 (29)	0.68
Medications
Corticosteroid use, n (%)	5 (42)	10 (45)	0.74
Immunosuppressive agent use, n (%)	3 (25)	2 (10)	0.33